These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32657189)

  • 1. Use of real-world evidence in meta-analyses and cost-effectiveness models.
    Bowrin K; Briere JB; Levy P; Toumi M; Millier A
    J Med Econ; 2020 Oct; 23(10):1053-1060. PubMed ID: 32657189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
    Briere JB; Wu O; Bowrin K; Millier A; Toumi M; Taieb V; Levy P; Coleman CI
    Curr Med Res Opin; 2019 Nov; 35(11):1867-1872. PubMed ID: 31328580
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analyses using real-world data: an overview of the literature.
    Bowrin K; Briere JB; Levy P; Millier A; Clay E; Toumi M
    J Med Econ; 2019 Jun; 22(6):545-553. PubMed ID: 30816067
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
    Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
    PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
    de Pouvourville G; Blin P; Karam P
    Eur J Health Econ; 2020 Mar; 21(2):235-249. PubMed ID: 31650440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
    Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C
    Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
    Lee W; Dayer V; Jiao B; Carlson JJ; Devine B; Veenstra DL
    J Manag Care Spec Pharm; 2021 Jan; 27(1):5-14. PubMed ID: 33377439
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.
    Camm AJ; Fox KAA; Peterson E
    Europace; 2018 Jan; 20(1):1-11. PubMed ID: 29040518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation.
    Limone BL; Baker WL; Mearns ES; White CM; Kluger J; Coleman CI
    J Clin Epidemiol; 2014 Oct; 67(10):1093-102. PubMed ID: 25018102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
    Jegathisawaran J; Holbrook A; Bowen JM; Burke N; Campbell K; Tarride JE
    J Popul Ther Clin Pharmacol; 2017 May; 24(2):e1-e20. PubMed ID: 28594478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 19. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.
    Liberato NL; Marchetti M
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):221-35. PubMed ID: 26817497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.